Peak Strength Bio
Research Use Only: For research use only. Not for human consumption. Content is educational and is not medical advice, diagnosis, or treatment.
Peptides / Peptides

PEP-TSM

Synthetic Growth Hormone-Releasing Hormone (GHRH) Analog for Metabolic and Neuroprotective Research

PEP-TSM

PEP-TSM is a modified, 44-amino-acid polypeptide that binds selectively to GHRH receptors in the anterior pituitary, stimulating the endogenous secretion of growth hormone and IGF-1. It is widely investigated in laboratory settings for its profound impact on visceral fat reduction, lean tissue preservation, and potential neuroprotective properties.

Typical dose
500 mcg to 2.0 mg subcutaneously per day (based on clinical literature)
Half-life
Approximately 26 to 38 minutes (pharmacokinetic studies in vivo)
Administration
Subcutaneous injection (highly prevalent in published literature)
Research status
Preclinical and clinical research ligand; therapeutic applications approved for specific pathological fat distribution states.
Calculate a dose

What Is PEP-TSM?

PEP-TSM is a synthetic peptide analog of growth hormone releasing hormone (GHRH) designed to stimulate natural growth hormone (GH) secretion. It was originally developed to reduce visceral fat in individuals with HIV associated lipodystrophy, and it has since gained broader research interest for metabolic and body composition related outcomes.

Mechanisms of Action

  • GH secretion stimulation by binding to GHRH receptors in the anterior pituitary, increasing GH release and elevating insulin like growth factor 1 (IGF 1) levels downstream.

  • Reduction in visceral fat through stimulation of lipolysis, contributing to reductions in abdominal fat in research models involving lipodystrophy and obesity.

  • Metabolic enhancement through improvements in lipid profiles, glucose metabolism, and insulin sensitivity, which is why it is discussed in metabolic syndrome and obesity related research contexts.

Benefits

  • Visceral fat reduction with emphasis on deep abdominal fat, including in research settings involving HIV associated lipodystrophy, metabolic syndrome, and central obesity.

  • Improved body composition by supporting lean muscle mass retention while reducing fat mass, contributing to muscle definition and overall metabolic health.

  • Metabolic benefits including support for improved cholesterol and triglyceride profiles and improved insulin sensitivity, with potential downstream relevance to Type 2 diabetes risk models.

Dosing

Strength

Dose

Low

.5-1 mg per day

Medium

1-1.5 mg per day

High

2 mg per day

Administration notes: subcutaneous injection is typically used daily. Often administered at least 90 minutes after the last meal and commonly timed before bedtime to align with natural GH secretion cycles.

Monitoring note: regular IGF 1 monitoring is commonly recommended in these discussions to support safety and inform dose adjustment.

Safety Profile

Tesamorelin is generally described as well tolerated, but some individuals may experience:

  • Mild injection site irritation such as redness or swelling.

  • Transient water retention can occur and may subside as the body adapts to GH stimulation.

  • Nausea or mild gastrointestinal discomfort is reported in some cases.

Because Tesamorelin increases IGF 1, individuals with a history of cancer or IGF 1 related concerns are typically advised to consult a healthcare professional before use.

Stacking

Fat Loss Stack

  • PEP-TSM

  • Retatrutide

  • SLU-PP-332

  • 5-Amino-1MQ

Muscle Growth Stack

  • PEP-TSM

  • Ipamorelin

  • IGF-1 LR3 (Advanced users only)

Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.

Where to source